Title: Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer

Journal: Targeted Oncology

Authors:

¹Lauren C. Bylsma, ²Xerxes Pundole, ²Chia-Hsin Ju, ¹Naushin Hooda, ¹Naimisha Movva, ²Ehab Elkhouly, ²Gwyn Bebb, ¹Jon Fryzek,
²Pablo Martinez, ²Akhila Balasubramanian, ³Anne-Marie C. Dingemans
¹EpidStrategies, a division of ToxStrategies, LLC, Mission Viejo, CA
²Amgen Inc., Thousand Oaks, CA
³Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands

Corresponding author: Lauren C Bylsma

Additional file 1. Search Strategy.

Term	PubMed
Study population	
	carcinoma, small cell lung[MeSH Terms] OR small cell lung cancer
SCLC	OR SCLC
Exposure	
	DLL3 protein, human[MeSH Terms] OR delta-like ligand 3 OR DLL3
DLL3	OR delta-like protein 3
Comparator	
N/A	
Outcome	
DLL3 Expression/Positivity	Express* OR positiv*
Prognostic Impact	Response OR survival OR progress* OR prognos*
Study type	
Observational studies, clinical trials, cases	
series with n≥20 patients	*
Inclusion criteria	
English language	Eng[la]

*Specific terms for study type not included to avoid accidental exclusion of studies not categorized under these terms.

Quality Rating	Threshold
Cohort and Case-Co	ontrol Studies
Good	3 or 4 points in selection domain AND 1 or 2 points in comparability domain AND 2 or 3 points in outcome/exposure domain
Fair	2 points in selection domain AND 1 or 2 points in comparability domain AND 2 or 3 points in outcome/exposure domain
Poor	0 or 1 points in selection domain OR 0 points in comparability domain OR 0 or 1 points in outcome/exposure domain
Cross-Sectional Stua	lies
Good	2 points in selection domain AND 1 or 2 points in comparability domain AND 2 points in outcome/exposure domain
Fair	1 point in selection domain AND 0 or 1 points in comparability domain AND 1 point in outcome/exposure domain
Poor	0 points in selection domain OR 0 points in outcome/exposure domain

Additional file 2. Conversion of Newcastle Ottawa Scale Scores to Agency for Healthcare Research and Quality (AHRQ) Standards.

Additional file 3. Study Characteristics of Included Studies, by SP347 Assays and Non-SP347 Assays (N=30 studies).

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
Ali, 2021[15]	Retrospe ctive cohort	Italy (2007- 2019)	32	78.1 %	NR	Never: 0% Current: 28.1% Former: 71.9%	SP347 NR	Assay State Limite d: 100% I: 31.2% II: 34.4% IV: 0%	NR	100% surgical resection ; no neoadjuv ant chemoth erapy or radiation	NR	IHC (Ventana SP347, NR)	High: ≥50% Low: <50% H-Score: High: ≥150 Low: <150	Prevale nce	Good
Brcic, 2019[16]	Cross- sectional	Germany (1996- 2012)	24	NR	NR	NR	NR	NR	NR	Chemo- naive	Chemo- naive	IHC (Ventana, SP347, NR)	High: ≥50% Positive: : ≥25% Cut-offs at 25, 50, and 75%	Prevale nce	Fair
Furuta, 2019[17]	Retrospe ctive cohort	Japan (2003- 2013)	95	77.9 %	NR	Never: 7.4% Current or former: 85.2% Unkno wn: 7.4%	0: 63.2% 1: 29.5% Unknow n: 7.4%	I: 74.7% II: 13.7% III: 11.6%	NR	100% surgical resection Adjuvant chemoth erapy: 63.2%	NR	IHC (Ventana, SP347, 4X)	High: ≥75% Low: <75%	Prevale nce Survival	Poor

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
Huang, 2019b[24]	Cross- sectional	United States (NR)	1362	NR	NR	NR	NR	NR	NR	NR	NR	IHC (Ventana SP347, NR)	NR	Prevale nce	Fair
Johnson, 2021[18]	Randomi zed controlle d trial, Phase III (MERU; NCT030 33511)	Multi- country (2017- 2019)	748 (372 interv ention ; 376 place bo)	Overa II: 66.4 Interv ention : 69.4 % Place bo: 63.6 %	Overal l: White: 82.2% Black or Africa n Ameri can: 1.2% Asian: 16.2% Ameri can Indian or Alaska Native : 0.3% Multip le races: 0.1%	NR	Status: Interventi on/Place bo 0: 39.0/40.0 % 1: 60.0/60.0 % Missing: 1.0/1.0%	Stage: Interve ntion/P lacebo IA: 0.0%/0 .3% IIB: 0.3/0.0 % IIIA: 1.0/1.0 % IIIB: 7.0/4.0 % IV: 77.0/7 8.0% Missin g: 16.0/1 6.0%	History of brain metasta ses- Interven tion: 15.0% Placebo : 15.0%	4 cycles of first- line platinum -based chemoth erapy	Mainten ance post 1L therapy	IHC (Ventana SP347, NR)	High: ≥75% Low: <75%	Prevale nce Respons e Survival	High risk

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
Kuempers , 2021[10]	Retrospe ctive cohort	Germany (NR)	42	64.3 %	NR	NR	NR	NR	NR	Platin- based chemoth erapy	NR	IHC (Ventana SP347, NR)	High $(\geq 50\%)$ Low (<50%) Positive: $\geq 1\%$ Cut-offs included 0, 1-49, and 50+% H-Score: High: ≥ 150 Low: <150	Prevale nce Survival	Poor
Messarita kis, 2019[19]	Prospecti ve cohort	Greece (NR)	108	84.3 %	NR	NR	NR	Limite d: 34.3% Extens ive: 65.7%	Liver metasta ses: 37.0% CNS metasta ses: 11.1% Bone metasta ses: 29.6%	NR	1	IHC (Ventana SP347, 20x and 4x)	High: ≥50% Low: <50%	Prevale nce	Good

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
Morgenszt ern, 2019[20]	Single- arm clinical trial, Phase II (TRINIT Y; NCT026 74568)	Multi- country (2016- 2017)	339	50%	NR	NR	0: 22.0% 1: 77.0% 2: 1.0%	IA: 2.0% IB: 1.0% IIA: 2.0% IIB: 1.0% IIIA: 11.0% IIIB: 13.0% IV: 66.0% Missin g: 1.0%	Brain metasta ses: 40.0% Pleural effusion s: 25.0%	Prior therapies (#)- 2: 77.0% 3: 15.0% >3: 8.0% Prior therapies - Platinum - containin g: 100.0% Topoteca n: 39.0% PD-1 inhibitor: 17.0% Other: 44.0%	3+	IHC (Ventana SP347, NR)	High: ≥75% Low: <75% Positive: ≥25%	Prevale nce Respons e Survival	Some concerns
Odashiro, 2020[21]	Cross- sectional	Canada (NR)	39	NR	NR	NR	NR	NR	NR	NR	NR	IHC (Ventana SP347, NR)	Cut-offs were <1, 1- 49, 50-74, and >75%	Prevale nce	Fair
Rojo, 2020[6]	Retrospe ctive cohort	Multi- country (2008- 2017)	1073	64.0 %	NR	Never: 7.0% Current: 57.0% Former: 32.0%	0: 25.0% 1: 37.0% 2: 15.0% 3: 7.0% 4: 1.0%	Limite d: 32.0% Extens ive: 63.0%	64.0%	Highest line received- None: 22.0% 1: 42.0%	1+	IHC (Ventana SP347, 4x)	High positive: ≥75% Non-high positive: 25-74%	Prevale nce Survival	Good

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
						Unkno wn: 4.0%	Missing: 16.0%	Missin g: 6.0%		2: 23.0% 2+: 14.0%			Positive: ≥25% Negative: 0-24%		
Tendler, 2020[25]	Cross- sectional	Sweden (2008- 2015)	46	43%	NR	NR	0: 28.0% 1: 35.0% 2: 28.0% 3: 7.0%	NR	Brain metasta ses: 60.9%	1 st line- Chemoth erapy alone: 82.0%	NR	IHC (Ventana SP347, 20x or 40x)	Unclear text	Prevale nce Survival	Good
Udagawa, 2019[22]	Single- arm clinical trial, phase I (NCT030 86239)	Japan (2017- 2018)	29	76%	NR	NR	0: 35.0% 1: 65.0%	NR	CNS metasta ses: 24.0%	Amrubici n: 100.0% Cisplatin : 72.0% Carbopla tin: 52.2% Etoposid e: 76.0% Irinoteca n: 59.0% Topoteca n: 14.0% PD-1 inhibitor: 3.0% Other: 45.0%	3+	IHC (Ventana SP347, NR)	High: ≥75% Low: <75% Positive: ≥25% Negative: <25%	Prevale nce Respons e Survival	Low risk

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
2019[23] (An, (Retrospe ctive cohort	United States (1995- 2017)	44	43.2 %	NR	NR	NR	NR	32.0%	NR	NR	IHC (Ventana- Roche SP347, 40x)	High: ≥50% Low: <50%	Prevale nce Survival	Good
					•		Non-SP3	47 Assay S	Studies						
An, 2018[26]	Cross- sectional	Korea (NR)	88	NR	NR	NR	NR	NR	NR	NR	NR	NR (NR, NR)	NR	Prevale nce	Fair
Calvo, 2021[27]	Single- arm clinical trial, Phase I (NCT030 002571)	Multi- country (2018- 2019)	31	41.9 %	NR	NR	0: 32.3% 1: 67.7%	NR	71.0%	Prior therapies - Cisplatin : 58.1% Carbopla tin: 51.6% Etoposid e: 80.6% Etoposid e + cisplatin: 9.7% Etoposid e + carboplat in: 3.2%	2+	IHC (Ventana, NR)	High: ≥75% Low: <75%	Prevale nce Respons e	Low risk
Fu, 2020[28]	Retrospe ctive cohort	China (2011- 2018)	43	81.4 %	NR	Current or former: 62.8%	NR	Limite d; 100% I: 32.6%	NR	100% surgical resection	NR	IHC (bs- 7860R, Bioss, China, NR)	Positive: NR	Prevale nce Survival	Poor

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
								II: 53.5% III: 14.0%							
Goldman, 2021[29]	Single- arm clinical trial, Phase I (NCT028 74664)	United States & Canada (2016- 2018)	46	39%	NR	Never: 4.0% Current: 17.0% Former: 78.0%	0: 26.0% 1: 70.0% 2: 4.0%	NR	NR	Platinum - containin g therapy: 100.0% Topoteca n: 15.0% Immunot herapy: 52.0%	2+	NR (NR, NR)	High: ≥75% Low: <75% Positive: ≥25%	Prevale nce	Low risk
Hu, 2022[41]	Retrospe ctive cohort	China (2005- 2016)	247	70.9 %	NR	History of smokin g: 64.0%	NR	I: 31.6% II: 27.5% III: 40.9%	NR	NR	NR	IHC (E3J5R, Cell Signal Technolog y, NR)	NR	Prevale nce Survival	Poor
Huang, 2019a[36]	Retrospe ctive cohort	China (2010- 2017)	72	NR	NR	NR	NR	NR	NR	Chemo- naive	1	IHC (ab103102 , Abcam, USA, NR)	NR	Prevale nce Respons e Survival	Poor
Li, 2022[30]	Prospecti ve cohort	China (2012- 2016)	134	85.1 %	NR	Heavy smokin g: 66.4% Moderat e	NR	IA: 21.6% IB: 11.9% IIA: 8.2%	NR	NR	NR	IHC (ab103102 , Abcam, USA, NR)	Positive (≥1%) Negative (<1%)	Prevale nce Survival	Poor

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
						smokin g: 6.7% Light smokin g: 3.0% Non- smokin g: 23.9%		IIB: 14.9% IIIA: 35.8% IIIB: 3.7% IV: 3.7%					Cut-offs were <1, 1- 60, and >60%		
Lim, 2019[37]	Retrospe ctive cohort	Korea (NR)	56	89.1 %	NR	NR	NR	NR	NR	Etoposid e and cisplatin: 90.9%	NR	IHC (AbbVie Stemcentr x, NR)	High: ≥50% Low: <50%	Prevale nce Survival	Poor
Malhotra, 2021[31]	Non- randomiz ed clinical trial, Phase I- II (NCT028 74664)	Multi- country (2017- 2019)	42 (30 group 1; 12 group 2)	Group 1: 53.3 % Group 2: 58.3 %	White: 92.9% Black: 4.8% Hispan ic or Latino: 4.8% Not Hispan ic or Latino: 92.9% NR: 2.4%	NR	0: 26.2% 1: 73.7%	NR	69.0%	Previous therapies - 1: 57.1% 2: 31.0% 3: 7.1% >3: 4.8%	2+	IHC (NR, NR)	High: ≥75% Low: <75%	Prevale nce	Some concerns
Obermayr , 2019[42]	Retrospe ctive cohort	Austria (NR)	48	62.5 %	NR	Never: 2.1% Current: 27.1%	NR	III: 11.4% IV: 88.6%	NR	NR	NR	RT-PCR (TaqMan)	NR	Prevale nce Survival	Poor

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
						Former: 54.2% Unkno wn: 16.7%		Unkno wn: 27.1%							
Prieto, 2021[38]	Cross- sectional	Brazil (NR)	22	63.6 %	NR	Smoker: 90.9% Unkno wn: 9.1%	NR	I: 8.7% II: 4.3% III: 8.7% IV: 52.2%	NR	NR	NR	NR (NR, NR)	NR	Prevale nce	Fair
Regzedma a, 2019[32]	Retrospe ctive cohort	China (2009- 2014)	38	68.4 %	NR	Never: 31.6% Ever: 68.4%	NR	I-II: 42.1% III-IV: 57.9%	60.5%	Chemo- naive	1	IHC (SAB1302 862, Sigma- Aldrich, China, NR)	High: ≥13.5% Low: <13.5%	Prevale nce Survival	Good
Roy, 2017[43]	Single- arm clinical trial, Phase I	NR (NR)	58	NR	NR	NR	NR	NR	NR	NR	NR	RT-PCR (NR, NR)	NR	Prevale nce	High risk
Rudin, 2017[33]	Non- randomiz ed clinical trial	United States (2013- 2015)	74	57%	NR	NR	0: 28.0% 1: 68.0% 2: 4.0%	NR	28.0%	Platinum + etoposide : 96.0% Platinum + another drug: 7.0%	2: 53.0% 3: 47.0%	IHC (Stemcent rx, USA, NR)	High: ≥50% Low: <50%	Prevale nce Respons e Survival	Some concerns

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
										Platinum + etoposide + another drug: 9.0% Topoteca n: 11.0% Temozol omide: 14.0% ABT- 888: 11.0% Radiatio n: 82.0% Other: 22.0%					
Saito, 2018[34]	Cross- sectional	Japan (1991- 2013)	20	100%	NR	Never: 5.0% Current or former: 95.0%	NR	I: 30.0% II: 5.0% III: 40.0% IV: 25.0%	10.0%	1 st treatment - Surgery: 45.0% Chemoth erapy only: 25.0% Radiatio n only: 5.0% Chemoth erapy +	2+	IHC (ab103102 , Abcam, USA, NR)	High: ≥50% Low: <50%	Prevale nce	Fair

Author, Year	Study design (Cohort name or NCT number, if applicab le)	Geograp hic Location (Dates)	N patie nts	Male sex (%)	Race/ Ethnic ity	Smokin g Status	ECOG Perform ance Status	Tumo r stage at Diagn osis	% With metasta ses	Treatme nt History	Line of Therap y for Curren t Treatm ent	DLL3 testing method (assay type, magnifica tion used)	DLL3 positivity threshold (% of tumor cell positivity and/or staining intensity and/or H- score)	Outco mes Report ed	AHRQ Quality Score (Observ ational) or Cochran e RoB (RCT)
										radiation: 20.0% 2 nd treatment - Surgery: 5.0% None: 95.0%					
Tanaka, 2018[35]	Cross- sectional	Japan (2012- 2016)	63	82.5 %	NR	Never: 4.8% Current or former: 95.2%	NR	Limite d: 41.3% Extens ive: 58.7%	22.2%	Chemo- naive	NR	IHC (AbbVie Stemcentr x, 20x or 40x)	High: \geq 50% Low: <50% Positive: \geq 1% Negative: <1%	Prevale nce Survival	Good
Yan, 2019[39]	Retrospe ctive cohort	China (2006- 2015)	335	91.3 %	NR	Non- smokers (<100 smokers in lifetime): 27.8% Smoker s: 72.2%	NR	I: 3.6% II: 5.1% III: 40.6% IV: 50.7%	Distant metasta sis: 50.7%	Chemo- naive	NR	IHC (ab103102 , Abcam, UK, NR)	H-Score: High: ≥150 Low: <150	Prevale nce Survival	Good

 ECOG: Eastern Cooperative Oncology Group; IHC: Immunohistochemistry; NR: not reported; RT-PCR: real-time polymerase chain reaction.

Additional file 4. Prevalence of Delta-Like Ligand 3 (DLL3) Expression in Small Cell Lung Cancer (SCLC) Patient Tissue Using Non-SP347 Assays (N=15 studies).*

Author, Year	Study Design (Cohort name or	Geographic Location	N Patients (Assay Used)	DLL3 positivity thresho (proportion of positive of		DLL3 Expression	H-Score threshold, N	
	NCT number, if applicable); population inclusion details	(Year)		Positive	Negative	High	Low	- (%)
An, 2018[26]	Cross-sectional; SCLC tumor samples	Korea (NR)	88 (NR)	Undefined: 38 (43.2%)	Undefined: 50 (56.8)	NR	NR	NR
Calvo, 2021[27]	Single-arm clinical trial, Phase I (NCT030002571); progressive SCLC	Multi- country (2018-2019)	24 ^a (NR)	≥1%: 22 (91.7)	0%: 2 (8.3)	≥75%: 19 (79.2)	<75%: 3 (12.5)	NR
Fu, 2020[28]	Retrospective cohort; SCLC surgical specimens	China (2011-2018)	43 (bs-7860R, Bioss, China)	Undefined: 28 (65.1)	Undefined: 15 (34.9)	NR	NR	NR
Goldman, 2021[29]	Single-arm clinical trial, Phase I (NCT02874664); previously- treated ES-SCLC patients	United States & Canada (2016-2018)	37 ^b (NR)	≥25%: 28 (75.7)	(0-24%): 9 (24.3)	≥75%: 21 (56.8)	<75%: 16 (43.2)	NR
Hu, 2022[41]	Retrospective cohort; SCLC surgical specimens	China (2005-2016)	247 (E3J5R, Cell Signal Technology)	NR	NR	NR	NR	High (undefined): 188 (72.8) Low (undefined): 59 (23.9)
Huang, 2019a[36]	Retrospective cohort; chemo- naïve surgical specimens	China (2010-2017)	72 (ab103102, Abcam, USA)	NR	NR	Undefined °: 23 (31.9)	Undefined ^c : 49 (68.1)	NR
Li, 2022[30]	Prospective cohort; SCLC surgical specimens	China (2012-2016)	101 ^d (ab103102, Abcam, USA)	≥1%: 87 (86.1)	<1%: 14 (13.9)	>60%: 54 (53.5)	1-60%: 33 (32.7)	NR

Author, Year	Study Design (Cohort name or	Geographic Location	N Patients (Assay Used)	DLL3 positivity thresho (proportion of positive)		DLL3 Expression (H-Score threshold, N	
	NCT number, if applicable); population inclusion details	(Year)		Positive	Negative	High	Low	- (%)
Lim, 2019[37]	Retrospective cohort; ES-SCLC tumor samples	Korea (NR)	56 (AbbVie Stemcentrx)	NR	NR	≥50%: 50 (89.3)	<50%: 6 (10.7)	NR
Malhotra, 2021[31]	Non-randomized clinical trial, Phase I-II (NCT02874664); previously- treated ES-SCLC	NR (NR-2019)	41 (29 group 1; 12 group 2) ^e (NR)	≥25%: 39 (95.1)	<25%: 2 (4.9)	≥75%: 23 (56.1)	<75%: 18 (43.9)	NR
Prieto, 2021[38]	Cross-sectional; SCLC surgical specimens	Brazil (NR)	22 (NR)	NR	NR	Undefined: 12 (54.5)	Undefined: 10 (45.5)	NR
Regzedmaa, 2019[32]	Retrospective cohort; SCLC surgical resections	China (2009-2014)	38 (SAB1302862, Sigma-Aldrich, China)	Undefined: 38 (100.0)	Undefined: 0 (0.0)	≥13.5%: 20 (52.6)	<13.5%: 18 (47.4)	NR
Rudin, 2017[33]	Non-randomized clinical trial; SCLC progressed after 1 or 2 chemotherapy treatments	United States (2013-2015)	48 ^f (Stemcentrx, USA)	≥1%: 42 (87.5)	<1%: 6 (12.5)	≥50%: 32 (66.7)	<50%: 16 (33.3)	NR
Saito, 2018[34]	Cross-sectional; SCLC samples from surgery or autopsy	Japan (1991-2013)	20 (ab103102, Abcam, USA)	≥1%: 18 (90.0)	<1%: 2 (10.0)	≥50%: 14 (70.0)	<50%: 6 (30.0)	NR
Tanaka, 2018[35]	Cross-sectional; SCLC tissue specimens	Japan (2012-2016)	63 (AbbVie Stemcentrx)	≥1%: 52 (82.5)	<1%: 11 (17.5)	≥50%: 20 (31.7)	<50%: 43 (68.3)	NR
Yan, 2019[39]	Retrospective cohort; <i>de novo</i> SCLC samples	China (2006-2015)	335 (ab103102, Abcam, UK)	NR	NR	NR	NR	High (≥150): 209 (62.4) Low (<150): 126 (37.6)

ES-SCLC: extensive-stage small cell lung cancer; NR: not reported. *Roy et al. 2017 and Obermayr et al. 2019 not included in this table as DLL3 expression was evaluated in circulating tumor cells rather than primary tumor tissue. ^a Calvo et al. 2021 included 31 patients but DLL3 expression was evaluated in 24 patients. ^b Goldman et al. 2021 included 46 patients but DLL3 expression was evaluated in 37 patients.

^c Huang 2019a categorized DLL3 expression as high or low based on the immune-reactive product score which is the product of proportion positive cells and staining intensity.
^d Li et al. 2022 included 134 patients but DLL3 expression was evaluated in 101 patients.
^e Malhotra et al. 2021 included 42 patients but DLL3 expression was evaluated in 41 patients.
^f Rudin et al. 2017 included 74 patients but DLL3 expression was evaluated in 48 patients.

Additional file 5. Stratification of Delta-Like Ligand 3 (DLL3) Expression in Small Cell Lung Cancer (SCLC) by Demographic and Clinical Factors, in Non-SP347 Assay Studies (N=8 studies).

Author, Year	DLL3 Expression (Definition)	N Patients	Age	Sex	Smoking Status	Stage
Fu, 2020[28]	Positive (undefined)	28	<60: 46.4% ≥60: 53.6%	Male: 82.1% Female:17.9%	Current/former: 39.3% Never: 60.7%	TNM Stage I: 39.3% II: 46.4% III: 14.3%
	Negative (undefined)	15	<60: 46.7% ≥60: 53.3%	Male: 80.0% Female: 20.0%	Current/former: 33.3% Never: 66.7%	TNM Stage I: 20.0% II: 66.7% III: 13.3%
	<i>p-value (univariat negative)</i>	e; positive vs.	0.988	0.863	0.700	0.393
Hu, 2022[41]	High (undefined)	188	≤65: 81.9% >65: 18.1%	Male: 69.7% Female:30.3%	Yes: 62.2% No: 37.8%	AJCC Stage I: 30.3% II: 26.1% III: 43.6%
	Low (undefined)	59	≤65: 81.4% >65: 18.6%	Male: 74.6% Female: 25.4%	Yes: 69.5% No: 30.5%	AJCC Stage I: 35.6% II: 32.2% III: 32.2%
	p-value (univariat	e; high vs. low)	1.00	0.52	0.35	0.28
Li, 2022[30]	≥60%	54	NR	NR	NR	NR
	1-60%	33	NR	NR	NR	NR
	<1%	14	NR	NR	NR	NR
	p-value (univariate; group difference)		>0.05	>0.05	>0.05	>0.05
Lim, 2019[37]	High (≥50%)	50	NR	NR	NR	NR
	Low (<50%)	6	NR	NR	NR	NR
	<i>p-value (univariate; high vs. low)</i>		>0.05	>0.05	>0.05	NR
Regzedmaa, 2019[32]	High (≥13.5%)	20	<58:45.0% >58: 55.0%	Male: 75.0% Female: 25.0%	Ever: 55.0% Never: 45.0%	AJCC Stage I-II: 30.0% III-IV: 70.0%
	Low (<13.5%)	18	<58:50.0% >58: 50.0%	Male: 61.1% Female: 38.9%	Ever: 83.3% Never: 16.7%	AJCC Stage I-II: 55.6% III-IV: 44.4%
	p-value (univariat	÷ .	1.00	0.489	0.086	0.188
Saito, 2018[34]	High (≥50%)	14	Median (IQR): 68 (59.8-77.5)	Male: 100% Female: 0%	Median (IQR) pack- years: 50 (36.3-67.5)	pStage: I: 33.3%

Author, Year	DLL3 Expression (Definition)	N Patients	Age	Sex	Smoking Status	Stage
						II: 0% III: 66.7% IV: 0%
	Low (<50%)	6	Median (IQR): 69.5 (61.3-77.5)	Male: 100% Female: 0%	Median (IQR) pack- years: 53 (30.3-80.3)	pStage: I: 28.6% II: 7.1% III: 28.6% IV: 35.7%
	p-value (univariat	te; high vs. low)	>0.05	>0.05	>0.05	>0.05
Tanaka, 2018[35]	high (≥50%)	20	≥70: 50% <70: 50%	Male: 90% Female: 10%	Brinkman Index: ≥1200: 40% <1200: 60%	Limited: 35% Extensive: 65%
	low (<50%)	43	≥70: 51.2% <70: 48.8%	Male: 79.1% Female: 20.9%	Brinkman Index: ≥1200: 44.2% <1200: 55.8%	Limited: 44.2% Extensive: 55.8%
	p-value (multivari	ate; high vs. low)	0.8015	0.2269	0.6042	0.4927
Yan, 2019[39]	High (H-score ≥ 150)	209	≤60: 44.0% >60: 56.0%	Male: 93.8% Female: 6.2%	Smokers: 76.6% Non-smokers: 23.4%	TNM Stage I: 3.3% II:4.8% III: 37.8% IV: 54.1%
	Low (H-score <150)	126	≤60: 40.5% >60: 59.5%	Male: 87.3% Female: 12.7%	Smokers: 65.1% Non-smokers: 34.9%	TNM Stage I: 4.0% II: 5.6% III: 45.2% IV: 45.2%
	p-value (univariat	e; high vs. low)	0.525	0.041	0.023	0.661

NR: not reported. **Bold** values indicate statistical significance (p<0.05).

Additional file 6. Small Cell Lung Cancer (SCLC) Treatment Response and Survival by Delta-Like Ligand 3 (DLL3) Expression Level in Tumor Tissue, in Non-SP347 Assay Studies (N=11 studies)^a.


Author, Year	Geographic Location (Dates)	DLL3 Expression (Definition)	N patients	Response	Overall Survival	Progression-Free Survival or Disease- Free Survival
0.1		(Definition)		Response Measure: % or median (95% CI)	Median (95% CI) or % by Milestone	Median (95% CI) or % by Milestone
Calvo, 2021[27]	Multi-country (2018-2019)	High (≥75%)	19	ORR: 21.1% (90% CI: 7.5, 41.9) CR (confirmed): 5.3% PR (confirmed): 15.8%	NR	NR
		Low (<75%)	3	NR	NR	NR
		HR (95% CI), p	-value	NR	NR	NR
Fu, 2020[28]	China (2011- 2018)	Positive (undefined)	28	NR	21 months	DFS: 21 months
	,	Negative (undefined)	15	NR	37 months	DFS: 36 months
		<i>p-value (univariate)</i>		NR	<i>p</i> =0.277	DFS: p=0.635
Hu, 2022[41]	China (2005- 2016)	High (undefined)	188	NR	NR	NR
		Low (undefined)	59	NR	NR	NR
		p-value (multivariate)		NR	<i>p</i> >0.05	DFS: p>0.05
Huang, 2019a[36]	China (2010- 2017)	High (undefined)	23	ORR: 34.8% DCR: 56.5%	NR	NR
		Low (undefined)	49	ORR: 63.3% DCR: 77.6%	NR	NR
		p-value (univari	ate)	ORR: p=0.041 DCR: p=0.095	<i>p<0.01</i>	<i>PFS: p<0.01</i>
Li, 2022[30]	China (2012-	≥60%	54	NR	NR	NR
	2016)	1-60%	33	NR	NR	NR
		<1%	14	NR	NR	NR
		p-value (univari	ate)	NR	<i>p</i> =0.886	DFS: p=0.873
Lim,	Korea (NR)	High (≥50%)	50	NR	5.3 months	PFS: 8.1 months
2019[37]		Low (<50%)	6	NR	8.3 months	PFS: 5.5 months
		p-value (univariate)		NR	<i>p</i> =0.975	<i>PFS: p=0.90</i>
	China	High (≥13.5%)	20	NR	12 months	NR

Author, Year	Geographic Location (Dates)	DLL3 Expression (Definition)	N patients	Response	Overall Survival	Progression-Free Survival or Disease- Free Survival
		(Definition)		Response Measure: % or median (95% CI)	Median (95% CI) or % by Milestone	Median (95% CI) or % by Milestone
Regzedmaa,	(2009-2014)	Low (<13.5%)	18	NR	23 months	NR
2019[32]		HR (95% CI), p (multivariate)	value	NR	3.12 (0.99, 9.82), p=0.000 ^b	NR
,	United States (2013-2015)	High (≥50%)	29°	ORR: 35.0% DCR: 89.7% DOR: 4.3 months (2.2- 15.0)	5.8 months (4.4, 11.6) 1-year OS: Refractory/ resistant: 29% Chemotherapy-sensitive: 33%	PFS: 4.3 months (2.8, 5.6)
			Low (<50%)	10°	ORR: 0.0% DCR: 60% DOR: 0 months	2.7 months (1.2, 10.0) 1-year OS: Refractory/ resistant: 0% Chemotherapy-sensitive: 23%
		HR (95% CI), p-value		NR	NR	NR
Tanaka,	Japan	High (≥50%)	20	NR	12.5 months	NR
2018[35]	(2012-2016)	Low (<50%)	43	NR	15.7 months	NR
		HR (95% CI), p (univariate)		NR	Overall: 0.975 (0.48-1.98), p=0.943 LD: 0.75 (0.174, 3.23), p=0.699 ED: 1.08 (0.473, 2.48), p=0.851	NR
Yan, 2019[39]	China (2006-2015)	High (H-score ≥150)	209	NR	NR	NR
		Low (H-score <150)	126	NR	NR	NR
		<i>p-value (multivariate)</i>		NR	<i>p</i> >0.05	NR

CBR: Clinical benefit rate; CI: Confidence Interval; CR: Complete response; DCR: Disease control rate; DFS: Disease-Free Survival; DOR: Duration of objective response; ED: Extensive disease; HR: Hazard Ratio; LD: Limited disease; NR: Not reported; ORR: Overall response rate; PR: Partial response. **Bold** values indicate statistical significance (p<0.05). ^a If multiple values are reported for an outcome, the most adjusted is presented here. Some papers indicated there were no significant associations (p>0.05) between DLL3 expression subgroups but did not report the actual numbers.


^b Regzedmaa et al. 2019 reported this HR as statistically significant (p=0.000), but the 95% CI includes 1.
 ^c Rudin et al. 2017 evaluated DLL3 expression in 48 patients but reported response and OS for 39 patients (29 high; 10 low) and PFS for 38 patients (29 high; 9 low).

Additional file 7. Summary of risk of bias scores in A) Observational studies (Newcastle-Ottawa Scale) and B) Clinical trials (Cochrane Risk of Bias Tool) among non-SP347 assay studies (N=17)



1A. Risk of Bias in Observational Studies (Newcastle-Ottawa Scale) Using Non-SP347 Assays (N=12 studies).

1B. Risk of Bias in Clinical Trials (Cochrane Risk of Bias Tool) Using SP347 Assays (N=5 studies).



Additional file 8. Supplemental Text

Study Characteristics: non-SP347

Among the 17 studies that used methods other than the Ventana SP347 IHC assay to evaluate DLL3 expression, most were observational in design, including 7 retrospective cohorts [28, 32, 36, 37, 39, 41, 42], 4 cross-sectional studies[26, 34, 35, 38], and one prospective cohort study [30] (Additional File 3). There were 5 clinical trials including 2 non-randomized [31, 33] and 3 single-arm trials [27, 29, 43]. Most (N=14) studies had less than 100 participants. Studies were conducted in China (N=6) [28, 30, 32, 36, 39, 41], Japan (N=2) [34, 35], Korea (N=2) [26, 37], the US (N=1) [33], multiple countries (N=3) [27, 29, 31], Austria (N=1) [42], Brazil (N=1) [38], and one study did not report the location[43].

Risk of Bias: non-SP347

The NOS scores of 12 observational studies that used methods other than the SP347 assay ranged from 3-9 with a mean of 5.75 and median of 5.5. When converted to the AHRQ standards, 4 studies were scored as good quality [23, 32, 35, 39], 3 were fair quality [26, 34, 38], and 5 were poor quality [28, 30, 36, 37, 41]. When evaluating bias by domain, risk was most apparent in the comparability and adequacy of follow-up (Additional File 7). In the Cochrane RoB scores of the 5 clinical trials that did not use SP347 assays, 3 studies were scored as high risk [31, 33, 43] and 2 had some concerns [27, 29]. Risk was most apparent in the randomization process (Additional File 7).

Patients and study characteristics: non-SP347

Patient and treatment characteristics varied across studies (Additional File 3). Sex was reported in 14 studies. The proportion of males ranged from 39% [29] in a Phase I trial of Rova-T in the US and Canada to 100% in a cross-sectional study of 20 patients with SCLC from Akita University, Japan (1991-2013) [34]. Only the Phase I-II trial of Rova-T reported race and/or ethnicity, with 93% of the study population being White [31]. Ten studies reported smoking status, of which most patients were current/former smokers (range: 62.8% in a retrospective cohort of 43 Chinese patients with SCLC from 2011-2018 [29] to 95.2% in a Japanese study of 63 patients with SCLC [35]). ECOG performance status was reported in 4 studies [27, 29, 31, 33], with the majority of patients having an ECOG performance status of \geq 1 (range 67.7% [28, 35]-74.0% [28, 30, 32, 34, 38, 39, 41, 42]). Nine studies reported tumor stage at diagnosis as limited or extensive [28, 35] and/or by TNM stage [28]. The proportion of patients with scLC [35]; the proportion with TNM Stage III-IV disease at diagnosis ranged from 14% in the same Chinese cohort [28] to 100% in the Austrian SCLC cohort [42].

DLL3 positivity was determined by percentage of primary tumor cell positivity in 13 studies [26-38] and/or H-score in 2 studies [39, 41]. Tumor cell positivity threshold ranged from 1-25% and was often classified as "high" or "low" with cut-offs at 50 or 75%. The threshold for "high" DLL3 expression using the H-score was 150 in one study [39] and not reported in the other [41]. One study classified DLL3 positivity as "high" or "low" based on the immuno-reactive product [36]. This score, between 0-12, was the product of the maximum staining intensity score (0=no staining, 1=weak, 2=moderate, 3=strong) and the percentage of positive cells score (0=no staining, 1=1-9%, 2=10-49%, 3=50-79%, 4= \geq 80%). In this study, all patients were ultimately assigned into DLL3-high group (scores \geq 6) or DLL3-low group (scores <6). Two studies investigated DLL3 expression in circulating tumor cells (CTC) of patients with SCLC rather than primary tumor tissue [42, 43]. Messaritakis et al. (2019) also evaluated DLL3 expression in CTC in addition to primary tumor tissue [19].

DLL3 testing methods varied across studies with three studies not reporting the DLL3 testing method. All 17 studies reported prevalence as an outcome, though 2 studies were based on DLL3 expression in CTC [42, 43]. Other endpoints assessed in the studies included stratification of DLL3 expression by demographic or clinical factors (n=8), overall survival (n=10), progression-free survival or disease-free survival (n=6), and treatment response (n=3).

DLL3 Prevalence and Associated Factors - non-SP347

Among the 15 studies that reported DLL3 expression prevalence in patient tumor tissue using assays other than SP347 (Additional File 4), the most commonly used methods to assess DLL3 expression were ab103102 (Abcam, USA) (N = 4; 26.7% [30, 34, 36, 39]) and Stemcentryx (N = 3; 20% [33, 35, 37]). Three (20%) other studies described additional methods (bs-7860R [28] [Bioss, China], E3J5R [41] [Cell Signaling Technology, USA], SAB1302862 [32] [Sigma-Aldrich, China]) and 5 (33.3%) other studies did not report the method used to test DLL3 expression [26, 27, 29, 31, 38].

DLL3 positivity was defined as $\geq 1\%$ of tumor cells in 5 studies [27, 30, 33-35]. The proportion of DLL3 positive patients ranged from 82.5% in a Japanese cohort of 63 patients with SCLC (2012-2016) [35] to 91.7% in a multi-country phase I trial of budigalimab and Rova-T in 24 patients with SCLC that had progressed on first-line platinum chemotherapy (2018-2019) [27]. Two studies defined positive DLL3 expression as $\geq 25\%$ of tumor cells; a multicenter trial of Rova-T in the US and Canada (2016-2018) [29] reported 75.7% of

patients with SCLC were DLL3-positive while a Phase 1-2 trial of Rova-T + nivolumab reported 95.1% of patients were positive for DLL3 [31]. DLL3 positivity threshold was undefined in 3 studies [26, 28, 32]; the prevalence of DLL3 positivity ranged from 43.2% in a conference abstract of a Korean cohort of 88 patients with SCLC [26] to 100.0% in a cohort of patients with primary resected SCLC from the Tianjin Medical University General Hospital, China, from 2009-2014 [32].

DLL3 expression was categorized as high (vs. low) in 11 studies [27, 29-38]. High DLL3 expression was defined as \geq 50% in 4 studies [33-35, 37]; prevalence ranged from 31.7% in a Japanese cohort of 63 patients with SCLC (2012-2016) [35] to 89.3% in a conference abstract of a Korean cohort of 56 patients with extensive stage SCLC [37]. High DLL3 expression was defined as \geq 75% in 3 studies [27, 29, 31] with the prevalence of high expression ranging from 56.1% in a Phase 1-2 trial of Rova-T + nivolumab [31] to 79.2% in a multi-country phase I trial of budigalimab and Rova-T in 24 patients with SCLC that had progressed on first-line platinum chemotherapy (2018-2019) [27]. DLL3 expression was also defined as high using cutoffs of 13.5% [32] and 60% [30] and was undefined in 2 other studies [36, 38].

Two studies defined high and low DLL3 expression using the H-score [39, 41]. One study of surgically resected samples with limited stage disease conducted in China from 2005-2016 classified "high" and "low" expression level according to the best cut-off value determined by Xtile software but the cut-off was not specified in the paper; this study reported DLL3-high prevalence of 72.8% [41]. Another cohort of 335 patients with *de novo* SCLC at the Guangdong Provincial People's Hospital (Guangzhou, China) from 2006-2015 used an H-score threshold of 150 to determine high vs. low DLL3 and reported 62.4% of patients as high [39].

The association between DLL3 expression and clinical or demographic factors was evaluated in 8 studies [28, 30, 32, 34, 35, 37, 39, 41], with all 8 studies investigating associations with patient age, sex, and smoking status/history, and 7 studies investigating an association with tumor stage (Additional File 5). All comparisons were univariate with the exception of the Japanese cohort of 63 patients with SCLC (2012-2016)[35], which conducted multivariate analyses adjusting for patient sex, age, disease stage, and smoking history. No statistically significant associations were reported between DLL3 expression and age or disease stage in any study. The association between DLL3 expression and sex or smoking status/history was null in 7 studies [28, 30, 32, 34, 35, 37, 41]. The cohort study of 335 patients with *de novo* SCLC at the Guangdong Provincial People's Hospital (Guangzhou, China) from 2006-2015, which defined high vs. low DLL3 expression using an H-score of 150, reported in univariate analysis that patients with high DLL3 expression had significantly higher proportion of male patients (vs. female, p=0.041) and smokers (vs. non-smokers, p=0.023)[39].

Hu et al. reported a significant univariate relationship between DLL3 expression and vascular invasion, with more DLL3-high patients (undefined) having vascular invasion than DLL3-low patients (p=0.045) in the cohort of patients with SCLC from the Chinese Academy of Medical Sciences Cancer Hospital from 2005-2016[41]. Yan et al. reported in univariate analyses that the DLL3-high group (H-score \geq 150) had a higher proportion of TTF-1-positive patients than the DLL3-low group in the cohort of Chinese patients with *de novo* SCLC from 2006-2015[39].

Circulating Tumor Cells (CTC) Studies

Among the 3 studies that evaluated DLL3 expression in CTC, cells were collected from patient blood samples and assessed for DLL3 expression using either RT-PCR[42, 43] or triple immunofluorescence assay[19]. The proportion of CTC that expressed DLL3 varied widely, from (7.8%) of samples in an Austrian cohort of patients with SCLC[42] to 63.8% at baseline in a Rova-T Phase 1 trial[43] and 74.1% of treatment-naïve Greek patients with SCLC[19]. The Greek cohort reported statistically significant univariate associations between baseline CTC expression of DLL3 and ECOG status, disease stage, LDH levels, and the presence of liver and bone metastases[19].

Survival and Response - non-SP347

Among the 15 studies that reported DLL3 expression in patient tumor tissue using assays other than SP347, there were 9 studies reporting the prognostic impact on overall survival (OS), 3 on progression-free survival (PFS), 3 on disease-free survival (DFS), and 3 on treatment response (Additional File 6).

OS was examined in 9 studies, 6 of which did not demonstrate any significant differences in survival by DLL3 expression in univariate[28, 30, 35, 37, 41] or multivariate[32, 36, 39] analysis. The cohort of *de novo* Chinese patients with SCLC from 2006-2015 reported significantly poorer survival among patients with DLL3-high (H-score \geq 150) patients compared with DLL3-low in univariate analysis, but the significance disappeared in multivariate models[33]. Significantly poorer survival was reported among DLL3-high (undefined) patients in univariate analysis of a Chinese cohort of patients with SCLC from 2010-2017[36]. While multivariate models in another Chinese cohort from 2009-2014 also reported significantly poorer OS among DLL3-high (\geq 13.5% of tumor cells) patients (p=0.000), the lower limit of the 95% confidence interval included 1, and it is unclear

whether the estimate was actually statistically significant (HR=3.12; 95% CI: 0.99-9.82)[32]. One study reported longer OS among DLL3-high (\geq 50% of tumor cells) patients than low (median OS 5.8 vs. 2.7 months, respectively) but statistical significance (i.e., a p-value) was not reported[33].

Three studies evaluated the prognostic impact of DLL3 expression on PFS with inconsistent results. A study of Chinese patients with SCLC reported a significant difference in PFS across DLL3 groups (p<0.01)[36] but another study of Korean patients with SCLC did not observe significant differences (p=0.90)[37]. One study reported longer PFS among DLL3-high (\geq 50% of tumor cells) patients than low (median PFS 4.3 vs. 2.2 months, respectively) but the study did not report a test for statistical significance[33]. DFS was examined in 3 studies; no statistically significant differences were reported between DLL3-high and DLL3-low groups in any study (p>0.05)[28, 30, 41].

The impact of DLL3 expression on treatment response was assessed in 3 non-SP347 assay studies. One study of Chinese patients with SCLC reported a significantly lower ORR among DLL3-high (undefined) patients compared to DLL3-low (34.8% vs. 63.3%, p=0.041)[36]. One study reported overall response rate (ORR) by DLL3 group (ORR for DLL3-high vs. DLL3-low: 35% vs. 0%) but the study did not report statistical significance[33]. The third study only reported ORR and partial response for the DLL3-high (\geq 75% of tumor cells) group; no comparisons were made with the DLL3-low group[27].

CTC Studies

The association between DLL3 expression in CTC and clinical outcome was evaluated within two studies. Within the Greek SCLC cohort, multivariate analyses adjusting for performance status, disease stage, LDH level, liver metastases, bone metastases, and treatment response demonstrated significantly poorer PFS among patients with DLL3+ CTC at baseline (HR=10.8, 95% CI: 2.1-56.4), but not OS (HR=1.8, 95% CI: 0.1-25.5). When evaluating DLL3 expression among CTC after the first cycle of frontline chemotherapy, no significant difference was observed for PFS but survival was significantly worse among patients with DLL3+ CTC (HR=28.2, 95% CI: 2.0-39.1)[19]. In samples from an Austrian cohort of patients with SCLC, OS was significantly lower among those with DLL3+ CTC in univariate Cox regression analyses (HR 3.79, 95% CI: 2.80-115.60; p=0.003)[42].